Clinical Trials for Sleep Apnea Progress as Over 22 Companies Contribute to Pipeline

The report underscores the strategies of major pharmaceutical firms advancing their pipelines, focusing on opportunities for future growth. Insights into clinical trial benchmarking, partnering, licensing activities, and regulatory pathways from the FDA and EMA are also detailed to facilitate informed decision-making for stakeholders.

Among the active companies working on sleep apnea therapies are Novo Nordisk A/S, Eli Lilly and Company, Innovent Biologics, and Apnimed. Notable drugs in development include Zenagamtide, IBI362, and AD109, with some drugs already in late-stage trials.

Mechanisms of action (MoAs) for these drugs cover a wide array of approaches including GLP-1 receptor agonists and norepinephrine reuptake inhibitors. Approximately eight sleep apnea drugs are reported to be in advanced stages of clinical development.

The report also details the implications of sleep apnea, a disorder characterized by interruptions in breathing during sleep. This condition, if untreated, can lead to serious health risks like cardiovascular disease and hypertension.

Recent advancements include Apnimed’s presentation regarding the FDA’s acceptance of the New Drug Application for AD109, targeting obstructive sleep apnea, with a review date set for February 28, 2027. Meanwhile, Mosanna Therapeutics reported the completion of an $80 million Series A funding round to develop a nasal spray treatment.

With the landscape shifting towards diverse therapeutic approaches, the report concludes that sleep apnea treatment options are likely to expand, adapting to patients’ unique needs.